Jaguar Health, Inc. current report, 26 April 2021

Full document

Jaguar Health, Inc. - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Jaguar Health, Inc. (JAGX) on April 30, 2021, covering events occurring on April 26, 2021, and April 29, 2021. The company is a Delaware corporation with principal executive offices in San Francisco, California.

Key Financial Metrics and Capital Events

  • Securities Offering: The Company entered into a Securities Purchase Agreement to sell 7,647,000 shares of Common Stock.
  • Gross Proceeds: The offering is expected to generate gross proceeds of $10,782,270.
  • Placement Fee: A placement agent fee of 8% of gross proceeds will be paid to Ladenburg Thalmann & Co. Inc.
  • Use of Proceeds: Net proceeds are intended for the benefit of the wholly-owned Italian subsidiary, Napo EU S.p.A., for capital expenditures, licenses, acquisitions, and strategic transactions. Unused proceeds after six months may be used for working capital and general corporate purposes.
  • ATM Program Termination: The Company terminated its At-The-Market (ATM) Offering Agreement. Under this program, the Company previously sold 5,824,479 shares for gross proceeds of approximately $7 million.

Material Changes

The primary material change is the shift in capital raising strategy from an "at-the-market" program to a registered public offering. The ATM program, which was active since October 5, 2020, was terminated effective April 26, 2021, and is no longer available for use.

Outlook, Risks, and Management Commentary

The offering is expected to close on May 3, 2021, subject to customary closing conditions. The filing notes that the Company is an emerging growth company. No specific financial guidance or risk factors beyond standard transaction contingencies are detailed in this specific 8-K text.

Investor Verification Checklist

  • Verify the closing date of the offering (expected May 3, 2021) and the final net proceeds after deducting the 8% placement fee and offering expenses.
  • Review the specific allocation of funds to the Italian subsidiary, Napo EU S.p.A., in subsequent filings.
  • Confirm the impact of the terminated ATM program on future liquidity and share issuance flexibility.
  • Check the prospectus supplement filed on April 30, 2021, for detailed terms of the 7,647,000 shares being sold.